Literature DB >> 33446323

The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer.

Sujit S Nair1, Rachel Weil2, Zachary Dovey2, Avery Davis2, Ashutosh K Tewari3.   

Abstract

Bladder cancer has been successfully treated with immunotherapy, whereas prostate cancer is a cold tumor with inadequate immune-related treatment response. A greater understanding of the tumor microenvironment and methods for harnessing the immune system to address tumor growth will be needed to improve immunotherapies for both prostate and bladder cancer. Here, we provide an overview of prostate and bladder cancer, including fundamental aspects of the disease and treatment, the elaborate cellular makeup of the tumor microenvironment, and methods for exploiting relevant pathways to develop more effective treatments.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Immunoediting; Immunotherapy; Neoadjuvant treatment; Prostate cancer; Tumor microenvironment; Vaccines

Year:  2020        PMID: 33446323     DOI: 10.1016/j.ucl.2020.10.005

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  6 in total

1.  Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution.

Authors:  Kevin Lu; Kun-Yuan Chiu; Chen-Li Cheng
Journal:  Cancer Treat Res       Date:  2022

2.  Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy.

Authors:  Kristian D Stensland; Theresa Devasia; Megan E V Caram; Christina Chapman; Alexander Zaslavsky; Todd M Morgan; Brent K Hollenbeck; Jordan B Sparks; Jennifer Burns; Varsha Vedapudi; Gillian M Duchesne; Alexander Tsodikov; Ted A Skolarus
Journal:  JNCI Cancer Spectr       Date:  2022-05-02

3.  Pyroptosis-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with UCEC.

Authors:  Jinhui Liu; Rui Geng; Senmiao Ni; Lixin Cai; Sheng Yang; Fang Shao; Jianling Bai
Journal:  Mol Ther Nucleic Acids       Date:  2022-01-25       Impact factor: 8.886

Review 4.  Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention.

Authors:  Sepideh Mirzaei; Mahshid Deldar Abad Paskeh; Elena Okina; Mohammad Hossein Gholami; Kiavash Hushmandi; Mehrdad Hashemi; Azuma Kalu; Ali Zarrabi; Noushin Nabavi; Navid Rabiee; Esmaeel Sharifi; Hassan Karimi-Maleh; Milad Ashrafizadeh; Alan Prem Kumar; Yuzhuo Wang
Journal:  J Exp Clin Cancer Res       Date:  2022-07-01

5.  Crosstalk of Redox-Related Subtypes, Establishment of a Prognostic Model and Immune Responses in Endometrial Carcinoma.

Authors:  Rui Geng; Jiahang Song; Zihang Zhong; Senmiao Ni; Wen Liu; Zhiqiang He; Shilin Gan; Qinghao Huang; Hao Yu; Jianling Bai; Jinhui Liu
Journal:  Cancers (Basel)       Date:  2022-07-12       Impact factor: 6.575

6.  Modified immunoscore improves the prediction of progression-free survival in patients with non-muscle-invasive bladder cancer: A digital pathology study.

Authors:  Uwe Bieri; Dominik Enderlin; Lorenz Buser; Marian S Wettstein; Daniel Eberli; Holger Moch; Thomas Hermanns; Cédric Poyet
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.